


L8 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2002:314929 CAPLUS  
 DOCUMENT NUMBER: 136:341001  
 TITLE: Preparation of substituted dipeptides as growth hormone secretagogues  
 INVENTOR(S): Dodge, Jeffrey Alan; Evers, Britta; Jungheim, Louis Nickolaus; Muehl, Brian Stephen; Ruehler, Gerd; Thrasher, Kenneth Jeff  
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA  
 SOURCE: PCT Int. Appl., 284 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

| PATENT NO.  | KIND | DATE              | APPLICATION NO. | DATE       |
|---|------|-------------------|-----------------|------------|
| WO 2002032888   | A1   | 20020425          | WO 2001-US27756 | 20011009   |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU |      |                   |                 |            |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  |      |                   |                 |            |
| CA 2419388  | AA   | 20020425          | CA 2001-2419388 | 20011009   |
| AU 2002011219   | A5   | 20020429          | AU 2002-11219   | 20011009   |
| BR 2001014630   | A    | 20030701          | BR 2001-14630   | 20011009   |
| EP 1326851  | A1   | 20030716          | EP 2001-979233  | 20011009   |
| EP 1326851  | B1   | 20040630          |                 |            |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR   |      |                   |                 |            |
| JP 2004511552   | T2   | 20040415          | JP 2002-536270  | 20011009   |
| AT 270280   | E    | 20040715          | AT 2001-979233  | 20011009   |
| PT 1326851  | T    | 20041130          | PT 2001-979233  | 20011009   |
| NZ 524232   | A    | 20050128          | NZ 2001-524232  | 20011009   |
| ES 2223926  | T3   | 20050301          | ES 2001-1979233 | 20011009   |
| ZA 2003001720   | A    | 20040621          | ZA 2003-1720    | 20030228   |
| US 2004058971   | A1   | 20040325          | US 2003-380867  | 20030314   |
| NO 2003001687   | A    | 20030508          | NO 2003-1687    | 20030411   |
| HR 20030288   | B1   | 20050228          | HR 2003-288     | 20030414   |
| HK 1058194  | A1   | 20050422          | HK 2003-109504  | 20031231   |
| PRIORITY APPLN. INFO.:  |      |                   | US 2000-240456P | P 20001013 |
|   |      |                   | WO 2001-US27756 | W 20011009 |
| OTHER SOURCE(S):  |      | MARPAT 136:341001 |                 |            |
| GI  |      |                   |                 |            |



AB The invention relates to novel dipeptides I [R1 = NHR10 or alkylNHR10, where R10 = H, alkyl, alkyl(OH), alkylidenyl(OH)R11 or an amino-protecting group and R11 = alkyl, alkenyl, alkyl(O)alkyl, carbalkoxy, aryl, alkylaryl; R2, R5, R8 = H, alkyl, aryl, alkylaryl; R3 = (un)substituted aryl, alkylaryl, alkyl(O)alkylaryl, cycloalkyl, alkylcycloalkyl, indolyl, indolinyl, alkylindolyl; R4 = H, alkyl, aryl, alkylaryl; W = CH<sub>2</sub>C<sub>6</sub>H<sub>4</sub> or (CH<sub>2</sub>)<sub>m</sub> (m = 1-4); R6, R7 = H, alkyl, alkenyl or R6R7C is carbocyclyl; R9 = H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cyano, (un)substituted aryl, etc.; Q = SO<sub>2</sub> or CO] or pharmaceutically acceptable salts, which are useful in the modulation of endogenous growth hormone levels in a mammal. Novel intermediates, processes employed in the syntheses, and methods of treating a mammal are included. Thus, amide (R)-2-(2-amino-2-methylpropionylamino)-3-phenylmethoxypropionic acid, N-[3-(4-chlorophenoxy)-2,2-dioxo-1-methyl-2-thia-1-azaspiro[4.5]dec-3-ene-4-ylmethyl]-N-ethylamide trifluoroacetate was prepared via acylation of 3-(4-chlorophenoxy)-4-(ethylaminomethyl)-1-methyl-2-thia-1-azaspiro[4.5]dec-3-ene 2,2-dioxide (preparation given) with Boc-protected acid. Compds. I showed activity in the pituitary cell culture assay for growth hormone secretion.

IT **416854-60-9P**


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of substituted dipeptides as growth hormone secretagogues)

RN 416854-60-9 CAPLUS

CN D-Serinamide, 2-methylalanyl-N-[(2,2-dioxido-3-phenyl-2-thia-1-azaspiro[4.4]non-3-en-4-yl)methyl]-N-ethyl-O-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



|    |                     |                     |                     |
|----|---------------------|---------------------|---------------------|
| IT | <u>416853-93-5P</u> | <u>416853-94-6P</u> | <u>416853-95-7P</u> |
|    | <u>416853-96-8P</u> | <u>416853-97-9P</u> | <u>416853-98-0P</u> |
|    | <u>416853-99-1P</u> | <u>416854-00-7P</u> | <u>416854-01-8P</u> |
|    | <u>416854-02-9P</u> | <u>416854-04-1P</u> | <u>416854-05-2P</u> |
|    | <u>416854-06-3P</u> | <u>416854-08-5P</u> | <u>416854-09-6P</u> |
|    | <u>416854-10-9P</u> | <u>416854-11-0P</u> | <u>416854-12-1P</u> |
|    | <u>416854-14-3P</u> | <u>416854-16-5P</u> | <u>416854-17-6P</u> |
|    | <u>416854-18-7P</u> | <u>416854-19-8P</u> | <u>416854-20-1P</u> |
|    | <u>416854-21-2P</u> | <u>416854-22-3P</u> | <u>416854-23-4P</u> |
|    | <u>416854-24-5P</u> | <u>416854-25-6P</u> | <u>416854-27-8P</u> |
|    | <u>416854-28-9P</u> | <u>416854-29-0P</u> | <u>416854-32-5P</u> |
|    | <u>416854-33-6P</u> | <u>416854-34-7P</u> | <u>416854-35-8P</u> |
|    | <u>416854-36-9P</u> | <u>416854-37-0P</u> | <u>416854-38-1P</u> |
|    | <u>416854-39-2P</u> | <u>416854-40-5P</u> | <u>416854-41-6P</u> |
|    | <u>416854-42-7P</u> | <u>416854-43-8P</u> | <u>416854-45-0P</u> |
|    | <u>416854-47-2P</u> | <u>416854-48-3P</u> | <u>416854-49-4P</u> |
|    | <u>416854-51-8P</u> | <u>416854-52-9P</u> | <u>416854-54-1P</u> |
|    | <u>416854-56-3P</u> | <u>416854-57-4P</u> | <u>416854-58-5P</u> |
|    | <u>416854-59-6P</u> | <u>416854-61-0P</u> | <u>416854-62-1P</u> |
|    | <u>416854-64-3P</u> | <u>416854-65-4P</u> | <u>416854-67-6P</u> |
|    | <u>416854-69-8P</u> | <u>416854-71-2P</u> | <u>416854-73-4P</u> |
|    | <u>416854-75-6P</u> | <u>416854-76-7P</u> | <u>416854-78-9P</u> |
|    | <u>416854-80-3P</u> | <u>416854-82-5P</u> | <u>416854-83-6P</u> |
|    | <u>416854-85-8P</u> | <u>416854-87-0P</u> | <u>416854-89-2P</u> |
|    | <u>416854-91-6P</u> | <u>416854-93-8P</u> | <u>416854-95-0P</u> |
|    | <u>416854-96-1P</u> | <u>416854-97-2P</u> | <u>416854-98-3P</u> |
|    | <u>416854-99-4P</u> | <u>416855-01-1P</u> | <u>416855-02-2P</u> |
|    | <u>416855-03-3P</u> | <u>416855-05-5P</u> | <u>416855-07-7P</u> |
|    | <u>416855-10-2P</u> | <u>416855-12-4P</u> | <u>416855-17-9P</u> |
|    | <u>416855-18-0P</u> | <u>416855-19-1P</u> | <u>416855-21-5P</u> |
|    | <u>416855-23-7P</u> | <u>416855-24-8P</u> | <u>416855-26-0P</u> |
|    | <u>416855-27-1P</u> | <u>416855-28-2P</u> | <u>416855-29-3P</u> |

**416855-30-6P 416855-31-7P 416855-32-8P**


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted dipeptides as growth hormone secretagogues)

RN 416853-93-5 CAPLUS

CN D-Serinamide, 2-methylalanyl-N-[[3-(4-chlorophenyl)-1-methyl-2,2-dioxido-2-thia-1-azaspiro[4.5]dec-3-en-4-yl)methyl]-N-ethyl-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 416853-94-6 CAPLUS


CN D-Serinamide, 2-methylalanyl-N-[[3-(4-chlorophenyl)-1-methyl-2,2-dioxido-2-thia-1-azaspiro[4.5]dec-3-en-4-yl)methyl]-N-ethyl-O-(phenylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 416853-93-5

CMF C32 H43 Cl N4 O5 S


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 416853-95-7 CAPLUS

CN D-Serinamide, 2-methylalanyl-N-[[3-(4-chlorophenyl)-2,2-dioxido-2-thia-1-azaspiro[4.5]dec-3-en-4-yl]methyl]-N-ethyl-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 416853-96-8 CAPLUS


CN D-Serinamide, 2-methylalanyl-N-[[3-(4-chlorophenyl)-2,2-dioxido-2-thia-1-azaspiro[4.5]dec-3-en-4-yl]methyl]-N-ethyl-O-(phenylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 416853-95-7

CMF C31 H41 Cl N4 O5 S


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 416853-97-9 CAPLUS

CN D-Serinamide, 2-methylalanyl-N-[[3-(4-chlorophenyl)-2,2-dioxido-2-thia-1-azaspiro[4.5]dec-3-en-4-yl]methyl]-N-methyl-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 416853-98-0 CAPLUS


CN D-Serinamide, 2-methylalanyl-N-[[3-(4-chlorophenyl)-2,2-dioxido-2-thia-1-azaspiro[4.5]dec-3-en-4-yl]methyl]-N-methyl-O-(phenylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 416853-97-9

CMF C30 H39 Cl N4 O5 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 416853-99-1 CAPLUS

CN D-Tryptophanamide, 2-methylalanyl-N-[[3-(4-chlorophenyl)-2,2-dioxido-2-thia-1-azaspiro[4.5]dec-3-en-4-yl)methyl]-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 416854-00-7 CAPLUS


CN D-Tryptophanamide, 2-methylalanyl-N-[[3-(4-chlorophenyl)-2,2-dioxido-2-thia-1-azaspiro[4.5]dec-3-en-4-yl]methyl]-N-ethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 416853-99-1

CMF C32 H40 Cl N5 O4 S


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 416854-01-8 CAPLUS

CN D-Norvalinamide, 2-methylalanyl-N-[[3-(4-chlorophenyl)-2,2-dioxido-2-thia-1-azaspiro[4.5]dec-3-en-4-yl]methyl]-N-ethyl-5-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 416854-02-9 CAPLUS


CN D-Norvalinamide, 2-methylalanyl-N-[[3-(4-chlorophenyl)-2,2-dioxido-2-thia-1-azaspiro[4.5]dec-3-en-4-yl]methyl]-N-ethyl-5-phenyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 416854-01-8

CMF C32 H43 Cl N4 O4 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 416854-04-1 CAPLUS


CN D-Serinamide, 2-methylalanyl-N-[[3-(4-chlorophenyl)-2,2-dioxido-2-thia-1-azaspiro[4.5]dec-3-en-4-yl)methyl]-O-(phenylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 416854-03-0

CMF C29 H37 Cl N4 O5 S


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 416854-05-2 CAPLUS

CN D-Serinamide, 2-methylalanyl-N-[[5-(4-chlorophenyl)-3,3-diethyl-2,3-dihydro-2-methyl-1,1-dioxido-4-isothiazolyl]methyl]-N-ethyl-O-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 416854-06-3 CAPLUS

CN D-Serinamide, 2-methylalanyl-N-[[5-(4-chlorophenyl)-2,3-dihydro-3,3-dimethyl-1,1-dioxido-4-isothiazolyl]methyl]-N-ethyl-O-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 416854-08-5 CAPLUS



CN D-Serinamide, 2-methylalanyl-N-[2-[3-(4-chlorophenyl)-2,2-dioxido-2-thia-1-azaspiro[4.5]dec-3-en-4-yl]ethyl]-N-ethyl-O-(phenylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 416854-07-4

CMF C32 H43 Cl N4 O5 S


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 416854-09-6 CAPLUS

CN D-Serinamide, 2-methylalanyl-N-[[3-[4-(1,1-dimethylethyl)phenyl]-2,2-dioxido-2-thia-1-azaspiro[4.5]dec-3-en-4-yl)methyl]-N-ethyl-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 416854-10-9 CAPLUS


CN D-Serinamide, 2-methylalanyl-N-[[3-[4-(1,1-dimethylethyl)phenyl]-2,2-dioxido-2-thia-1-azaspiro[4.5]dec-3-en-4-yl)methyl]-N-ethyl-O-(phenylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 416854-09-6

CMF C35 H50 N4 O5 S


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 416854-11-0 CAPLUS

CN D-Serinamide, 2-methylalanyl-N-[[3-(4-chlorophenyl)-2,2-dioxido-2-thia-1-azaspiro[4.5]dec-3-en-4-yl]methyl]-O-(phenylmethyl)-N-propyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 416854-12-1 CAPLUS

CN D-Serinamide, 2-methylalanyl-N-[[3-(4-chlorophenyl)-2,2-dioxido-2-thia-1-azaspiro[4.5]dec-3-en-4-yl]methyl]-O-(phenylmethyl)-N-propyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 416854-11-0



CMF C32 H43 Cl N4 O5 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 416854-14-3 CAPLUS


CN D-Serinamide, 2-methylalanyl-N-butyl-N-[[3-(4-chlorophenyl)-2,2-dioxido-2-thia-1-azaspiro[4.5]dec-3-en-4-yl)methyl]-O-(phenylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 416854-13-2

CMF C33 H45 Cl N4 O5 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 416854-16-5 CAPLUS


CN D-Serinamide, 2-methylalanyl-N-[[3-(4-chlorophenyl)-2,2-dioxido-2-thia-1-azaspiro[4.5]dec-3-en-4-yl]methyl]-N,O-bis(phenylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 416854-15-4

CMF C36 H43 Cl N4 O5 S


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 416854-17-6 CAPLUS

CN D-Norvalinamide, 2-methylalanyl-N-[[3-(4-chlorophenyl)-2,2-dioxido-2-thia-1-azaspiro[4.5]dec-3-en-4-yl]methyl]-N-methyl-5-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 416854-18-7 CAPLUS


CN D-Norvalinamide, 2-methylalanyl-N-[[3-(4-chlorophenyl)-2,2-dioxido-2-thia-1-azaspiro[4.5]dec-3-en-4-yl]methyl]-N-methyl-5-phenyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 416854-17-6

CMF C31 H41 Cl N4 O4 S


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 416854-19-8 CAPLUS

CN D-Serinamide, 2-methylalanyl-N-ethyl-N-[(1-methyl-2,2-dioxido-3-phenyl-2-thia-1-azaspiro[4.5]dec-3-en-4-yl)methyl]-O-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 416854-20-1 CAPLUS

CN D-Serinamide, 2-methylalanyl-N-[(2,2-dioxido-3-phenyl-2-thia-1-azaspiro[4.5]dec-3-en-4-yl)methyl]-N-ethyl-O-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 416854-21-2 CAPLUS

CN D-Serinamide, 2-methylalanyl-N-[[3-(3-chlorophenyl)-1-methyl-2,2-dioxido-2-thia-1-azaspiro[4.5]dec-3-en-4-yl]methyl]-N-ethyl-O-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 416854-22-3 CAPLUS

CN D-Serinamide, 2-methylalanyl-N-[[3-(2-chlorophenyl)-1-methyl-2,2-dioxido-2-thia-1-azaspiro[4.5]dec-3-en-4-yl]methyl]-N-ethyl-O-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 416854-23-4 CAPLUS

CN D-Serinamide, 2-methylalanyl-N-ethyl-N-[[1-methyl-2,2-dioxido-3-[4-(trifluoromethyl)phenyl]-2-thia-1-azaspiro[4.5]dec-3-en-4-yl]methyl]-O-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 416854-24-5 CAPLUS

CN D-Serinamide, 2-methylalanyl-N-ethyl-N-[[1-methyl-3-(4-nitrophenyl)-2,2-dioxido-2-thia-1-azaspiro[4.5]dec-3-en-4-yl]methyl]-O-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 416854-25-6 CAPLUS

CN D-Serinamide, 2-methylalanyl-N-[[3-(4-bromophenyl)-2,2-dioxido-2-thia-1-



azaspiro[4.5]dec-3-en-4-yl)methyl]-N-ethyl-O-(phenylmethyl)-,  
monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 416854-27-8 CAPLUS


CN D-Serinamide, 2-methylalanyl-N-[[2,2-dioxido-3-[3-(trifluoromethyl)phenyl]-  
2-thia-1-azaspiro[4.5]dec-3-en-4-yl)methyl]-N-ethyl-O-(phenylmethyl)-,  
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 416854-26-7

CMF C32 H41 F3 N4 O5 S


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 416854-28-9 CAPLUS

CN D-Serinamide, 2-methylalanyl-N-ethyl-N-[[3-(4-methylphenyl)-2,2-dioxido-2-thia-1-azaspiro[4.5]dec-3-en-4-yl]methyl]-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 416854-29-0 CAPLUS


CN D-Serinamide, 2-methylalanyl-N-ethyl-N-[[3-(4-methylphenyl)-2,2-dioxido-2-thia-1-azaspiro[4.5]dec-3-en-4-yl]methyl]-O-(phenylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 416854-28-9

CMF C32 H44 N4 O5 S


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 416854-32-5 CAPLUS

CN D-Serinamide, 2-methylalanyl-N-ethyl-N-[(1-ethyl-2,2-dioxido-3-phenyl-2-thia-1-azaspiro[4.5]dec-3-en-4-yl)methyl]-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 416854-33-6 CAPLUS


CN D-Serinamide, 2-methylalanyl-N-ethyl-N-[(1-ethyl-2,2-dioxido-3-phenyl-2-thia-1-azaspiro[4.5]dec-3-en-4-yl)methyl]-O-(phenylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 416854-32-5

CMF C33 H46 N4 O5 S


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 416854-34-7 CAPLUS

CN D-Serinamide, 2-methylalanyl-N-[[2,2-dioxido-3-(3-phenoxyphenyl)-2-thia-1-azaspiro[4.5]dec-3-en-4-yl]methyl]-N-ethyl-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 416854-35-8 CAPLUS


CN D-Serinamide, 2-methylalanyl-N-[[2,2-dioxido-3-(3-phenoxyphenyl)-2-thia-1-azaspiro[4.5]dec-3-en-4-yl]methyl]-N-ethyl-O-(phenylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 416854-34-7

CMF C37 H46 N4 O6 S


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 416854-36-9 CAPLUS

CN D-Serinamide, 2-methylalanyl-N-[[3-(3-bromophenyl)-2,2-dioxido-2-thia-1-azaspiro[4.5]dec-3-en-4-yl]methyl]-N-ethyl-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 416854-37-0 CAPLUS


CN D-Serinamide, 2-methylalanyl-N-[[3-(3-bromophenyl)-2,2-dioxido-2-thia-1-azaspiro[4.5]dec-3-en-4-yl]methyl]-N-ethyl-O-(phenylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 416854-36-9

CMF C31 H41 Br N4 O5 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 416854-38-1 CAPLUS

CN D-Norvalinamide, 2-methylalanyl-N-[(2,2-dioxido-3-phenyl-2-thia-1-azaspiro[4.5]dec-3-en-4-yl)methyl]-N-ethyl-5-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 416854-39-2 CAPLUS


CN D-Norvalinamide, 2-methylalanyl-N-[(2,2-dioxido-3-phenyl-2-thia-1-azaspiro[4.5]dec-3-en-4-yl)methyl]-N-ethyl-5-phenyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 416854-38-1


CMF C32 H44 N4 O4 S

Absolute stereochemistry.




CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 416854-40-5 CAPLUS  
CN D-Serinamide, 2-methylalanyl-N-ethyl-N-[[3-(4-fluorophenyl)-2,2-dioxido-2-thia-1-azaspiro[4.5]dec-3-en-4-yl)methyl]-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 416854-41-6 CAPLUS  
CN D-Serinamide, 2-methylalanyl-N-ethyl-N-[[3-(4-fluorophenyl)-2,2-dioxido-2-thia-1-azaspiro[4.5]dec-3-en-4-yl)methyl]-O-(phenylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 416854-40-5  
CMF C31 H41 F N4 O5 S


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 416854-42-7 CAPLUS

CN D-Norvalinamide, 2-methylalanyl-N-ethyl-N-[[3-(4-fluorophenyl)-2,2-dioxido-2-thia-1-azaspiro[4.5]dec-3-en-4-yl]methyl]-5-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 416854-43-8 CAPLUS


CN D-Norvalinamide, 2-methylalanyl-N-ethyl-N-[[3-(4-fluorophenyl)-2,2-dioxido-2-thia-1-azaspiro[4.5]dec-3-en-4-yl]methyl]-5-phenyl-,  
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 416854-42-7

CMF C32 H43 F N4 O4 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 416854-45-0 CAPLUS


CN D-Serinamide, 2-methylalanyl-N-[[3-(2-chlorophenyl)-2,2-dioxido-2-thia-1-azaspiro[4.5]dec-3-en-4-yl]methyl]-N-ethyl-O-(phenylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 416854-44-9


CMF C31 H41 Cl N4 O5 S

Absolute stereochemistry.



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 416854-47-2 CAPLUS  
CN D-Serinamide, 2-methylalanyl-N-[(3-[1,1'-biphenyl]-4-yl-2,2-dioxido-2-thia-1-azaspiro[4.5]dec-3-en-4-yl)methyl]-N-ethyl-O-(phenylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 416854-46-1  
CMF C37 H46 N4 O5 S

Absolute stereochemistry.



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 416854-48-3 CAPLUS

CN D-Serinamide, 2-methylalanyl-N-[[3-(2-bromophenyl)-2,2-dioxido-2-thia-1-azaspiro[4.5]dec-3-en-4-yl]methyl]-N-ethyl-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 416854-49-4 CAPLUS


CN D-Serinamide, 2-methylalanyl-N-[[3-(2-bromophenyl)-2,2-dioxido-2-thia-1-azaspiro[4.5]dec-3-en-4-yl]methyl]-N-ethyl-O-(phenylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 416854-48-3

CMF C31 H41 Br N4 O5 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 416854-51-8 CAPLUS

CN D-Norvalinamide, 2-methylalanyl-N-[[3-(2-bromophenyl)-2,2-dioxido-2-thia-1-azaspiro[4.5]dec-3-en-4-yl]methyl]-N-ethyl-5-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 416854-52-9 CAPLUS


CN D-Norvalinamide, 2-methylalanyl-N-[[3-(2-bromophenyl)-2,2-dioxido-2-thia-1-azaspiro[4.5]dec-3-en-4-yl)methyl]-N-ethyl-5-phenyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 416854-51-8

CMF C32 H43 Br N4 O4 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 416854-54-1 CAPLUS


CN D-Serinamide, 2-methylalanyl-N-[[3-(4-cyanophenyl)-2,2-dioxido-2-thia-1-azaspiro[4.5]dec-3-en-4-yl)methyl]-N-ethyl-O-(phenylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 416854-53-0


CMF C32 H41 N5 O5 S

Absolute stereochemistry.



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 416854-56-3 CAPLUS  
CN D-Serinamide, 2-methylalanyl-N-[[3-[4-(aminocarbonyl)phenyl]-2,2-dioxido-2-thia-1-azaspiro[4.5]dec-3-en-4-yl]methyl]-N-ethyl-O-(phenylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 416854-55-2  
CMF C32 H43 N5 O6 S

Absolute stereochemistry.



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 416854-57-4 CAPLUS

CN D-Serinamide, 2-methylalanyl-N-[(2,3-dihydro-3,3-dimethyl-1,1-dioxido-5-phenyl-4-isothiazolyl)methyl]-N-ethyl-O-(phenylmethyl)-, hydrochloride (5:7) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●7/5 HCl

RN 416854-58-5 CAPLUS

CN D-Norvalinamide, 2-methylalanyl-N-[(2,3-dihydro-3,3-dimethyl-1,1-dioxido-5-phenyl-4-isothiazolyl)methyl]-N-ethyl-5-phenyl-, hydrochloride (5:6) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●6/5 HCl

RN 416854-59-6 CAPLUS

CN D-Norvalinamide, 2-methylalanyl-N-[[5-(4-chlorophenyl)-2,3-dihydro-3,3-dimethyl-1,1-dioxido-4-isothiazolyl]methyl]-N-ethyl-5-phenyl-, hydrochloride (5:8) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●8/5 HCl

RN 416854-61-0 CAPLUS

CN D-Norvalinamide, 2-methylalanyl-N-[(2,2-dioxido-3-phenyl-2-thia-1-azaspiro[4.4]non-3-en-4-yl)methyl]-N-ethyl-5-phenyl-, hydrochloride (2:5) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●5/2 HCl

RN 416854-62-1 CAPLUS

CN D-Serinamide, 2-methylalanyl-N-[[3-(4-chlorophenyl)-2,2-dioxido-2-thia-1-azaspiro[4.4]non-3-en-4-yl]methyl]-N-ethyl-O-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 416854-64-3 CAPLUS


CN D-Serinamide, 2-methylalanyl-N-ethyl-N-[[3-(4-methoxyphenyl)-2-oxo-1-azaspiro[4.5]dec-3-en-4-yl)methyl]-O-(phenylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 416854-63-2

CMF C33 H44 N4 Q5


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 416854-65-4 CAPLUS

CN D-Serinamide, 2-methylalanyl-N-ethyl-N-[[3-(4-methoxyphenyl)-1-methyl-2-oxo-1-azaspiro[4.5]dec-3-en-4-yl]methyl]-O-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 416854-67-6 CAPLUS


CN D-Serinamide, 2-methylalanyl-N-[[3-(4-methoxyphenyl)-2-oxo-1-azaspiro[4.5]dec-3-en-4-yl]methyl]-O-(phenylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 416854-66-5

CMF C31 H40 N4 O5

Absolute stereochemistry.






CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 416854-69-8 CAPLUS


CN D-Serinamide, 2-methylalanyl-N-[[4-(4-chlorophenyl)-2,2-diethyl-2,5-dihydro-5-oxo-1H-pyrrol-3-yl]methyl]-N-ethyl-O-(phenylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 416854-68-7

CMF C31 H41 Cl N4 O4


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 416854-71-2 CAPLUS


CN D-Serinamide, 2-methylalanyl-N-[[3-(4-chlorophenoxy)-2-oxo-1-azaspiro[4.5]dec-3-en-4-yl]methyl]-N-ethyl-O-(phenylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 416854-70-1

CMF C32 H41 Cl N4 O5


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 416854-73-4 CAPLUS


CN D-Serinamide, 2-methylalanyl-N-[[3-(3-chlorophenyl)-2-oxo-1-azaspiro[4.5]dec-3-en-4-yl]methyl]-N-ethyl-O-(phenylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 416854-72-3

CMF C32 H41 Cl N4 O4


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 416854-75-6 CAPLUS

CN D-Serinamide, 2-methylalanyl-N-[[3-(2-chlorophenyl)-2-oxo-1-azaspiro[4.5]dec-3-en-4-yl]methyl]-N-ethyl-O-(phenylmethyl)-,


mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 416854-74-5

CMF C32 H41 Cl N4 O4


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 416854-76-7 CAPLUS

CN D-Serinamide, 2-methylalanyl-N-[[3-(4-chlorophenyl)-2-oxo-1-azaspiro[4.5]dec-3-en-4-yl]methyl]-N-ethyl-O-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 416854-78-9 CAPLUS


CN D-Serinamide, 2-methylalanyl-N-[[3-(4-bromophenyl)-2-oxo-1-azaspiro[4.5]dec-3-en-4-yl]methyl]-N-ethyl-O-(phenylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 416854-77-8

CMF C32 H41 Br N4 O4

Absolute stereochemistry.




CM 2

CRN 76-05-1  
CMF C2 H F3 O2RN 416854-80-3 CAPLUS  
CN D-Serinamide, 2-methylalanyl-N-ethyl-N-[[3-(4-fluorophenyl)-2-oxo-1-azaspiro[4.5]dec-3-en-4-yl)methyl]-O-(phenylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 416854-79-0  
CMF C32 H41 F N4 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 416854-82-5 .CAPLUS.  
CN D-Serinamide, 2-methylalanyl-N-ethyl-N-[[3-(4-methylphenyl)-2-oxo-1-azaspiro[4.5]dec-3-en-4-yl)methyl]-O-(phenylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 416854-81-4  
CMF C33 H44 N4 O4

Absolute stereochemistry.



CM 2.


CRN 76-05-1  
CMF C2 H F3 O2



RN 416854-83-6 CAPLUS

CN D-Serinamide, 2-methylalanyl-N-[(3-[1,1'-biphenyl]-4-yl-2-oxo-1-azaspiro[4.5]dec-3-en-4-yl)methyl]-N-ethyl-O-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 416854-85-8 CAPLUS

CN D-Serinamide, 2-methylalanyl-N-ethyl-N-[(2-oxo-3-phenyl-1-azaspiro[4.5]dec-3-en-4-yl)methyl]-O-(phenylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 416854-84-7

CMF C32 H42 N4 O4

Absolute stereochemistry.






CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 416854-87-0 CAPLUS


CN D-Serinamide, 2-methylalanyl-N-ethyl-N-[[2-oxo-3-(2-thienyl)-1-azaspiro[4.5]dec-3-en-4-yl]methyl]-O-(phenylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 416854-86-9

CMF C30 H40 N4 O4 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 416854-89-2 CAPLUS


CN D-Serinamide, 2-methylalanyl-N-ethyl-N-[(1-methyl-2-oxo-3-phenyl-1-azaspiro[4.5]dec-3-en-4-yl)methyl]-O-(phenylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 416854-88-1

CMF C33 H44 N4 O4


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 416854-91-6 CAPLUS


CN D-Serinamide, 2-methylalanyl-N-ethyl-N-[[1-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1-azaspiro[4.5]dec-3-en-4-yl]methyl]-O-(phenylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 416854-90-5

CMF C34 H43 F3 N4 O4


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 416854-93-8 CAPLUS


CN D-Serinamide, 2-methylalanyl-N-[(3-[1,1'-biphenyl]-4-yl-1-methyl-2-oxo-1-azaspiro[4.5]dec-3-en-4-yl)methyl]-N-ethyl-O-(phenylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 416854-92-7

CMF C39 H48 N4 O4


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 416854-95-0 CAPLUS


CN D-Serinamide, 2-methylalanyl-N-[[3-(4-chlorophenyl)-1-methyl-2-oxo-1-azaspiro[4.5]dec-3-en-4-yl]methyl]-N-ethyl-O-(phenylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 416854-94-9

CMF C33 H43 Cl N4 O4


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 416854-96-1 CAPLUS

CN D-Serinamide, 2-methylalanyl-N-[[4-(4-chlorophenyl)-2,5-dihydro-2,2-dimethyl-5-oxo-1H-pyrrol-3-yl]methyl]-N-ethyl-O-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 416854-97-2 CAPLUS

CN D-Serinamide, 2-methylalanyl-N-[[4-(4-bromophenyl)-2,5-dihydro-2,2-dimethyl-5-oxo-1H-pyrrol-3-yl)methyl]-N-ethyl-O-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 416854-98-3 CAPLUS

CN D-Serinamide, 2-methylalanyl-N-ethyl-N-[(2-oxo-3-phenoxy-1-azaspiro[4.5]dec-3-en-4-yl)methyl]-O-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 416854-99-4 CAPLUS

CN D-Serinamide, 2-methylalanyl-N-[[3-(4-chlorophenoxy)-1-methyl-2-oxo-1-azaspiro[4.5]dec-3-en-4-yl]methyl]-N-ethyl-O-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl



RN 416855-01-1 CAPLUS


CN D-Serinamide, 2-methylalanyl-N-ethyl-N-[[2-oxo-3-[3-(trifluoromethyl)phenyl]-1-azaspiro[4.5]dec-3-en-4-yl]methyl]-O-(phenylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 416855-00-0

CMF C33 H41 F3 N4 O4


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 416855-02-2 CAPLUS

CN D-Serinamide, 2-methylalanyl-N-[[3-(3,4-dichlorophenyl)-2-oxo-1-azaspiro[4.5]dec-3-en-4-yl]methyl]-N-ethyl-O-(phenylmethyl)-,

monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 416855-03-3 CAPLUS

CN D-Serinamide, 2-methylalanyl-N-[2-[3-(2-chlorophenyl)-2-oxo-1-azaspiro[4.5]dec-3-en-4-yl]ethyl]-N-ethyl-O-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 416855-05-5 CAPLUS

CN D-Serinamide, 2-methylalanyl-N-ethyl-N-[[3-(1-naphthalenyl)-2,2-dioxido-2-


thia-1-azaspiro[4.5]dec-3-en-4-yl)methyl]-O-(phenylmethyl)-,  
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 416855-04-4

CMF C35 H44 N4 O5 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 416855-07-7 CAPLUS


CN D-Serinamide, 2-methylalanyl-N-ethyl-N-[[3-(2-naphthalenyl)-2,2-dioxido-2-thia-1-azaspiro[4.5]dec-3-en-4-yl)methyl]-O-(phenylmethyl)-,  
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 416855-06-6

CMF C35 H44 N4 O5 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 416855-10-2 CAPLUS


CN D-Serinamide, 2-methylalanyl-N-ethyl-N-[[3-[4-(methylsulfonyl)phenyl]-2,2-dioxido-2-thia-1-azaspiro[4.5]dec-3-en-4-yl]methyl]-O-(phenylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 416855-09-9

CMF C32 H44 N4 O7 S2


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 416855-12-4 CAPLUS

CN D-Serinamide, 2-methylalanyl-N-[[5-(4-chlorophenyl)-2,3-dihydro-3,3-dimethyl-1,1-dioxido-4-isothiazolyl]methyl]-N-ethyl-O-(phenylmethyl)-, hydrochloride (10:11) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●11/10 HCl

RN 416855-17-9 CAPLUS

CN D-Serinamide, 2-methylalanyl-N-ethyl-N-[(1-methyl-2,2-dioxido-3-phenyl-2-thia-1-azaspiro[4.5]dec-3-en-4-yl)methyl]-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 416855-18-0 CAPLUS

CN D-Serinamide, 2-methylalanyl-N-[[3-(3-chlorophenyl)-1-methyl-2,2-dioxido-2-thia-1-azaspiro[4.5]dec-3-en-4-yl)methyl]-N-ethyl-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 416855-19-1 CAPLUS

CN D-Serinamide, 2-methylalanyl-N-[[3-(2-chlorophenyl)-1-methyl-2,2-dioxido-2-thia-1-azaspiro[4.5]dec-3-en-4-yl]methyl]-N-ethyl-O-(phenylmethyl)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 416855-21-5 CAPLUS

CN D-Serinamide, 2-methylalanyl-N-ethyl-N-[[1-methyl-2,2-dioxido-3-[4-

(trifluoromethyl)phenyl]-2-thia-1-azaspiro[4.5]dec-3-en-4-yl)methyl]-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 416855-23-7 CAPLUS

CN D-Serinamide, 2-methylalanyl-N-ethyl-N-[[1-methyl-3-(4-nitrophenyl)-2,2-dioxido-2-thia-1-azaspiro[4.5]dec-3-en-4-yl)methyl]-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 416855-24-8 CAPLUS

CN D-Serinamide, 2-methylalanyl-N-[[3-(4-bromophenyl)-2,2-dioxido-2-thia-1-azaspiro[4.5]dec-3-en-4-yl)methyl]-N-ethyl-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 416855-26-0 CAPLUS

CN D-Serinamide, 2-methylalanyl-N-[(2,3-dihydro-3,3-dimethyl-1,1-dioxido-5-phenyl-4-isothiazolyl)methyl]-N-ethyl-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 416855-27-1 CAPLUS

CN D-Norvalinamide, 2-methylalanyl-N-[(2,3-dihydro-3,3-dimethyl-1,1-dioxido-5-phenyl-4-isothiazolyl)methyl]-N-ethyl-5-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 416855-28-2 CAPLUS

CN D-Serinamide, 2-methylalanyl-N-[(2,2-dioxido-3-phenyl-2-thia-1-azaspiro[4.4]non-3-en-4-yl)methyl]-N-ethyl-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 416855-29-3 CAPLUS

CN D-Norvalinamide, 2-methylalanyl-N-[[5-(4-chlorophenyl)-2,3-dihydro-3,3-dimethyl-1,1-dioxido-4-isothiazolyl]methyl]-N-ethyl-5-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 416855-30-6 CAPLUS

CN D-Norvalinamide, 2-methylalanyl-N-[(2,2-dioxido-3-phenyl-2-thia-1-azaspiro[4.4]non-3-en-4-yl)methyl]-N-ethyl-5-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 416855-31-7 CAPLUS

CN D-Serinamide, 2-methylalanyl-N-[[3-(4-chlorophenyl)-2,2-dioxido-2-thia-1-azaspiro[4.4]non-3-en-4-yl)methyl]-N-ethyl-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 416855-32-8 CAPLUS

CN D-Serinamide, 2-methylalanyl-N-[(2,2-dioxido-3-phenyl-2-thia-1-azaspiro[4.5]dec-3-en-4-yl)methyl]-N-ethyl-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



|    |                     |                     |                     |
|----|---------------------|---------------------|---------------------|
| IT | <u>416855-36-2P</u> | <u>416855-45-3P</u> | <u>416855-49-7P</u> |
|    | <u>416855-53-3P</u> | <u>416855-59-9P</u> | <u>416855-62-4P</u> |
|    | <u>416855-66-8P</u> | <u>416855-70-4P</u> | <u>416855-74-8P</u> |
|    | <u>416855-78-2P</u> | <u>416855-93-1P</u> | <u>416855-96-4P</u> |
|    | <u>416856-07-0P</u> | <u>416856-08-1P</u> | <u>416856-10-5P</u> |
|    | <u>416856-16-1P</u> | <u>416856-17-2P</u> | <u>416856-23-0P</u> |

416856-30-9P 416856-33-2P 416856-36-5P416856-41-2P 416856-49-0P 416856-59-2P416856-63-8P 416856-73-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)

(preparation of substituted dipeptides as growth hormone secretagogues)

RN 416855-36-2 CAPLUS

CN D-Serinamide, N-[(1,1-dimethylethoxy)carbonyl]-2-methylalanyl-N-[[3-(4-chlorophenyl)-1-methyl-2,2-dioxido-2-thia-1-azaspiro[4.5]dec-3-en-4-yl)methyl]-N-ethyl-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 416855-45-3 CAPLUS

CN D-Serinamide, N-[(1,1-dimethylethoxy)carbonyl]-2-methylalanyl-N-[[5-(4-chlorophenyl)-3,3-diethyl-2,3-dihydro-2-methyl-1,1-dioxido-4-isothiazolyl)methyl]-N-ethyl-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 416855-49-7 CAPLUS

CN D-Serinamide, N-[(1,1-dimethylethoxy)carbonyl]-2-methylalanyl-N-[[5-(4-chlorophenyl)-2,3-dihydro-3,3-dimethyl-1,1-dioxido-4-isothiazolyl]methyl]-N-ethyl-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 416855-53-3 CAPLUS

CN D-Serinamide, N-[(1,1-dimethylethoxy)carbonyl]-2-methylalanyl-N-[[3-[4-(1,1-dimethylethyl)phenyl]-2,2-dioxido-2-thia-1-azaspiro[4.5]dec-3-en-4-yl]methyl]-N-ethyl-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 416855-59-9 CAPLUS

CN D-Serinamide, N-[(1,1-dimethylethoxy)carbonyl]-2-methylalanyl-N-ethyl-N-[(1-methyl-2,2-dioxido-3-phenyl-2-thia-1-azaspiro[4.5]dec-3-en-4-yl)methyl]-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 416855-62-4 CAPLUS

CN D-Serinamide, N-[(1,1-dimethylethoxy)carbonyl]-2-methylalanyl-N-[(2,2-

dioxido-3-phenyl-2-thia-1-azaspiro[4.5]dec-3-en-4-yl)methyl]-N-ethyl-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 416855-66-8 CAPLUS

CN D-Serinamide, N-[(1,1-dimethylethoxy) carbonyl]-2-methylalanyl-N-[[3-(3-chlorophenyl)-1-methyl-2,2-dioxido-2-thia-1-azaspiro[4.5]dec-3-en-4-yl)methyl]-N-ethyl-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 416855-70-4 CAPLUS

CN D-Serinamide, N-[(1,1-dimethylethoxy)carbonyl]-2-methylalanyl-N-[[3-(2-chlorophenyl)-1-methyl-2,2-dioxido-2-thia-1-azaspiro[4.5]dec-3-en-4-yl)methyl]-N-ethyl-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 416855-74-8 CAPLUS

CN D-Serinamide, N-[(1,1-dimethylethoxy)carbonyl]-2-methylalanyl-N-ethyl-N-[[1-methyl-2,2-dioxido-3-[4-(trifluoromethyl)phenyl]-2-thia-1-azaspiro[4.5]dec-3-en-4-yl)methyl]-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 416855-78-2 CAPLUS

CN D-Serinamide, N-[(1,1-dimethylethoxy)carbonyl]-2-methylalanyl-N-ethyl-N-[[1-methyl-3-(4-nitrophenyl)-2,2-dioxido-2-thia-1-azaspiro[4.5]dec-3-en-4-yl)methyl]-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 416855-93-1 CAPLUS

CN D-Serinamide, N-[(1,1-dimethylethoxy)carbonyl]-2-methylalanyl-N-ethyl-N-[[3-(4-fluorophenyl)-2,2-dioxido-2-thia-1-azaspiro[4.5]dec-3-en-4-yl)methyl]-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 416855-96-4 CAPLUS

CN D-Serinamide, N-[(1,1-dimethylethoxy)carbonyl]-2-methylalanyl-N-[[3-(2-chlorophenyl)-2,2-dioxido-2-thia-1-azaspiro[4.5]dec-3-en-4-yl)methyl]-N-ethyl-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 416856-07-0 CAPLUS

CN D-Serinamide, N-[(1,1-dimethylethoxy)carbonyl]-2-methylalanyl-N-[(2,3-dihydro-3,3-dimethyl-1,1-dioxido-5-phenyl-4-isothiazolyl)methyl]-N-ethyl-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 416856-08-1 CAPLUS

CN D-Norvalinamide, N-[(1,1-dimethylethoxy)carbonyl]-2-methylalanyl-N-[(2,3-dihydro-3,3-dimethyl-1,1-dioxido-5-phenyl-4-isothiazolyl)methyl]-N-ethyl-5-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 416856-10-5 CAPLUS

CN D-Norvalinamide, N-[(1,1-dimethylethoxy)carbonyl]-2-methylalanyl-N-[[5-(4-chlorophenyl)-2,3-dihydro-3,3-dimethyl-1,1-dioxido-4-isothiazolyl]methyl]-N-ethyl-5-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 416856-16-1 CAPLUS

CN D-Serinamide, N-[(1,1-dimethylethoxy)carbonyl]-2-methylalanyl-N-[(2,2-dioxido-3-phenyl-2-thia-1-azaspiro[4.4]non-3-en-4-yl)methyl]-N-ethyl-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 416856-17-2 CAPLUS

CN D-Norvalinamide, N-[(1,1-dimethylethoxy)carbonyl]-2-methylalanyl-N-[(2,2-dioxido-3-phenyl-2-thia-1-azaspiro[4.4]non-3-en-4-yl)methyl]-N-ethyl-5-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 416856-23-0 CAPLUS

CN D-Serinamide, N-[(1,1-dimethylethoxy)carbonyl]-2-methylalanyl-N-[[3-(4-chlorophenyl)-2,2-dioxido-2-thia-1-azaspiro[4.4]non-3-en-4-yl]methyl]-N-ethyl-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 416856-30-9 CAPLUS

CN D-Serinamide, N-[(1,1-dimethylethoxy)carbonyl]-2-methylalanyl-N-ethyl-N-[[3-(4-methoxyphenyl)-2-oxo-1-azaspiro[4.5]dec-3-en-4-yl]methyl]-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 416856-33-2 CAPLUS

CN D-Serinamide, N-[(1,1-dimethylethoxy)carbonyl]-2-methylalanyl-N-ethyl-N-[[3-(4-methoxyphenyl)-1-methyl-2-oxo-1-azaspiro[4.5]dec-3-en-4-yl]methyl]-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 416856-36-5 CAPLUS

CN D-Serinamide, N-[(1,1-dimethylethoxy)carbonyl]-2-methylalanyl-N-[[3-(4-methoxyphenyl)-2-oxo-1-azaspiro[4.5]dec-3-en-4-yl]methyl]-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 416856-41-2 CAPLUS

CN D-Serinamide, N-[(1,1-dimethylethoxy) carbonyl]-2-methylalanyl-N-[[4-(4-chlorophenyl)-2,2-diethyl-2,5-dihydro-5-oxo-1H-pyrrol-3-yl]methyl]-N-ethyl-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 416856-49-0 CAPLUS

CN D-Serinamide, N-[(1,1-dimethylethoxy) carbonyl]-2-methylalanyl-N-[[3-(4-chlorophenyl)-2-oxo-1-azaspiro[4.5]dec-3-en-4-yl]methyl]-N-ethyl-O-



(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 416856-59-2 CAPLUS

CN D-Serinamide, N-[(1,1-dimethylethoxy)carbonyl]-2-methylalanyl-N-[(2-oxo-3-phenyl-1-azaspiro[4.5]dec-3-en-4-yl)methyl]-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 416856-63-8 CAPLUS

CN D-Serinamide, N-[(1,1-dimethylethoxy)carbonyl]-2-methylalanyl-N-[(2-oxo-3-phenyl-1-azaspiro[4.5]dec-3-en-4-yl)methyl]-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

[[2-oxo-3-(2-thienyl)-1-azaspiro[4.5]dec-3-en-4-yl]methyl]-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 416856-73-0 CAPLUS

CN D-Serinamide, N-[(1,1-dimethylethoxy)carbonyl]-2-methylalanyl-N-[[3-(4-chlorophenyl)-1-methyl-2-oxo-1-azaspiro[4.5]dec-3-en-4-yl]methyl]-N-ethyl-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT